{"id":"vb-111-paclitaxel","safety":{"commonSideEffects":[{"rate":"null","effect":"Fatigue"},{"rate":"null","effect":"Nausea"},{"rate":"null","effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"The combination of VB-111 and Paclitaxel targets both the tumor vasculature and the rapidly dividing cancer cells, leading to a synergistic anti-tumor effect. VB-111 binds to VEGF, preventing it from interacting with its receptor and thereby inhibiting angiogenesis, while Paclitaxel stabilizes microtubules, preventing cell division and leading to cell death.","oneSentence":"VB-111 is a targeted anti-vascular endothelial growth factor (VEGF) aptamer that inhibits tumor growth by blocking VEGF, while Paclitaxel is a microtubule inhibitor that disrupts cell division.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:54:47.027Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Recurrent Glioblastoma"}]},"trialDetails":[{"nctId":"NCT03398655","phase":"PHASE3","title":"A Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer (OVAL)","status":"COMPLETED","sponsor":"Vascular Biogenics Ltd. operating as VBL Therapeutics","startDate":"2017-12-19","conditions":"Recurrent Platinum Resistant Ovarian Cancer","enrollment":408},{"nctId":"NCT01711970","phase":"PHASE1, PHASE2","title":"A Phase I/II Trial of VB-111 and Paclitaxel for Recurrent Platinum-Resistant Müllerian Cancer","status":"COMPLETED","sponsor":"Vascular Biogenics Ltd. operating as VBL Therapeutics","startDate":"2012-11","conditions":"Platinum Resistant Ovarian Cancer","enrollment":38}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Ofranergene Obadenovec"],"phase":"phase_3","status":"active","brandName":"VB-111 + Paclitaxel","genericName":"VB-111 + Paclitaxel","companyName":"Vascular Biogenics Ltd. operating as VBL Therapeutics","companyId":"vascular-biogenics-ltd-operating-as-vbl-therapeutics","modality":"Small molecule","firstApprovalDate":"","aiSummary":"VB-111, a small molecule inhibitor of Toll-like receptor 2, is being studied in combination with Paclitaxel for the treatment of recurrent platinum-resistant ovarian cancer. The study, NCT03398655, is a randomized, double-blind, controlled trial comparing VB-111 + Paclitaxel to Placebo + Paclitaxel and Paclitaxel alone.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}